Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-22
2010-10-12
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S307000, C514S311000, C514S320000, C514S405000, C514S456000, C544S151000, C546S139000, C546S152000, C546S184000, C548S361100, C549S404000
Reexamination Certificate
active
07812019
ABSTRACT:
Compounds that are antagonists of the VR1 receptor, having formula (I)or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
REFERENCES:
patent: 5374643 (1994-12-01), Atwal et al.
patent: WO-03097586 (2003-11-01), None
patent: WO-2004078744 (2004-09-01), None
patent: WO-2007050732 (2007-05-01), None
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chemical Reviews, 1996, vol. 96, pp. 3147-3176.
Bognar et al. “Flavonoids, XII. Synthesis of 4-Ureido-flavan and Di-(4-flavanyl)-urea” Acta. Chim. Hung. Trans, 1963, vol. 35, pp. 223-224.
Caterina et al., “Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor,”Science288:306-313 (2000).
Caterina et al., “The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway,”Nature389:816-824 (Oct. 23 1997).
Caterina et al., “The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway,”Annu. Rev. Neurosci. 24:487-517 (2001).
Collier et al., “The Abdominal Constriction Response and its Suppression by Analgesic Drugs in the Mouse,”Br. J. Pharmacol. Chemother. 32:295-310 (1968).
Dade, J., “Synthesis of 2-Substituated Trifluoromethylquinolines for the Evaluation of Leishmanicidal Activity”,Chem. Pharm. Bull., vol. 49(4), pp. 480-483, (2001).
Davis et al., “Vanilloid Receptor-1 is Essential for Inflammatory Thermal Hyperalgesia,”Nature405:183-187 (2000).
Fowler, “Intravesical Treatment of Overactive Bladder,”Urology55(Supplement 5A):60-64 (2000).
Hayes et al., “Cloning and Functional Expression of a Human Orthologue of Rat Vanilloid Receptor-1”,Pain88:205-215 (2000).
Nolano et al., “Topical Capsaicin in Humans: Parallel Loss of Epidermal Nerve Fibers and Pain Sensation,”Pain81:135-145 (1999).
Pircio, et al., “A New Method for the Evaluation of Analgesic Activity using Adjuvant-Induced Arthritis in the Rat”Eur J. Pharmacol. vol. 31(2) pp. 207-215 (1975).
Bognar rezso et al., “Flavanoids XII. Synthesis of 4-ureldoflavan and bis (4flavanyl) urea,” Acts Chim Acad. Sci, 1963, 223-224, vol. 35.
Database Beilstein Beilstein Institute for Organic Chemistry, Frank Furt-Main, DE; XP002507218 Database accession No. brn 355828 abstract and Webster et al: J.Chem.Soc. , 1965, pp. 4785-4789.
International Search Report for application No. PCT/US05/042545, Mailed on Feb. 19, 2009, 3 pages.
Bayburt Erol K.
Brown Brian S.
Daanen Jerome F.
Gomtsyan Arthur
Jinkerson Tammie K.
Abbott Laboratories
Kosack Joseph R
Parial Andrew M.
LandOfFree
Chromanylurea compounds that inhibit vanilloid receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chromanylurea compounds that inhibit vanilloid receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromanylurea compounds that inhibit vanilloid receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172612